Investigating a new treatment target for pulmonary hypertension in COPD patients
Matrikines and COPD-PH
This study is looking at how a part of the body called AcPGP affects lung blood pressure in people with COPD, and it aims to find new ways to help improve treatment for those dealing with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10683144 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific fragment of the extracellular matrix, known as AcPGP, contributes to pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD). The researchers will explore the mechanisms by which AcPGP affects inflammatory cells and leads to changes in the pulmonary blood vessels. By using both animal models and human cohorts, they aim to identify new therapeutic targets that could improve treatment options for COPD-PH. The study will also assess the clinical implications of these findings for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic obstructive pulmonary disease who also experience pulmonary hypertension.
Not a fit: Patients without chronic obstructive pulmonary disease or those who do not have pulmonary hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with pulmonary hypertension associated with COPD.
How similar studies have performed: While the specific approach of targeting AcPGP in COPD-PH is novel, similar research has shown promise in exploring extracellular matrix components in other pulmonary conditions.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wells, James Michael — University of Alabama at Birmingham
- Study coordinator: Wells, James Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.